The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Conjugate Vaccines Market Research Report 2024

Global Conjugate Vaccines Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1413899

No of Pages : 87

Synopsis
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
The global Conjugate Vaccines market was valued at US$ 9995.1 million in 2023 and is anticipated to reach US$ 12920 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Conjugate Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Conjugate Vaccines.
Report Scope
The Conjugate Vaccines market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Conjugate Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Conjugate Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Neuron Biotech
Serum Institute of India
Pfizer
Sanofi Pasteur
Bharat Biotech
Biological
GlaxoSmithKline
Merck
CSL
Segment by Type
Monovalent Conjugate Vaccines
Multivalent Conjugate Vaccines
Segment by Application
Children
Adults
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Conjugate Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Conjugate Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Conjugate Vaccines Market Overview
1.1 Product Overview and Scope of Conjugate Vaccines
1.2 Conjugate Vaccines Segment by Type
1.2.1 Global Conjugate Vaccines Market Value Comparison by Type (2024-2030)
1.2.2 Monovalent Conjugate Vaccines
1.2.3 Multivalent Conjugate Vaccines
1.3 Conjugate Vaccines Segment by Application
1.3.1 Global Conjugate Vaccines Market Value by Application: (2024-2030)
1.3.2 Children
1.3.3 Adults
1.4 Global Conjugate Vaccines Market Size Estimates and Forecasts
1.4.1 Global Conjugate Vaccines Revenue 2019-2030
1.4.2 Global Conjugate Vaccines Sales 2019-2030
1.4.3 Global Conjugate Vaccines Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Conjugate Vaccines Market Competition by Manufacturers
2.1 Global Conjugate Vaccines Sales Market Share by Manufacturers (2019-2024)
2.2 Global Conjugate Vaccines Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Conjugate Vaccines Average Price by Manufacturers (2019-2024)
2.4 Global Conjugate Vaccines Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Conjugate Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Conjugate Vaccines, Product Type & Application
2.7 Conjugate Vaccines Market Competitive Situation and Trends
2.7.1 Conjugate Vaccines Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Conjugate Vaccines Players Market Share by Revenue
2.7.3 Global Conjugate Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Conjugate Vaccines Retrospective Market Scenario by Region
3.1 Global Conjugate Vaccines Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Conjugate Vaccines Global Conjugate Vaccines Sales by Region: 2019-2030
3.2.1 Global Conjugate Vaccines Sales by Region: 2019-2024
3.2.2 Global Conjugate Vaccines Sales by Region: 2025-2030
3.3 Global Conjugate Vaccines Global Conjugate Vaccines Revenue by Region: 2019-2030
3.3.1 Global Conjugate Vaccines Revenue by Region: 2019-2024
3.3.2 Global Conjugate Vaccines Revenue by Region: 2025-2030
3.4 North America Conjugate Vaccines Market Facts & Figures by Country
3.4.1 North America Conjugate Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Conjugate Vaccines Sales by Country (2019-2030)
3.4.3 North America Conjugate Vaccines Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Conjugate Vaccines Market Facts & Figures by Country
3.5.1 Europe Conjugate Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Conjugate Vaccines Sales by Country (2019-2030)
3.5.3 Europe Conjugate Vaccines Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Conjugate Vaccines Market Facts & Figures by Country
3.6.1 Asia Pacific Conjugate Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Conjugate Vaccines Sales by Country (2019-2030)
3.6.3 Asia Pacific Conjugate Vaccines Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Conjugate Vaccines Market Facts & Figures by Country
3.7.1 Latin America Conjugate Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Conjugate Vaccines Sales by Country (2019-2030)
3.7.3 Latin America Conjugate Vaccines Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Conjugate Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Conjugate Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Conjugate Vaccines Sales by Country (2019-2030)
3.8.3 Middle East and Africa Conjugate Vaccines Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Conjugate Vaccines Sales by Type (2019-2030)
4.1.1 Global Conjugate Vaccines Sales by Type (2019-2024)
4.1.2 Global Conjugate Vaccines Sales by Type (2025-2030)
4.1.3 Global Conjugate Vaccines Sales Market Share by Type (2019-2030)
4.2 Global Conjugate Vaccines Revenue by Type (2019-2030)
4.2.1 Global Conjugate Vaccines Revenue by Type (2019-2024)
4.2.2 Global Conjugate Vaccines Revenue by Type (2025-2030)
4.2.3 Global Conjugate Vaccines Revenue Market Share by Type (2019-2030)
4.3 Global Conjugate Vaccines Price by Type (2019-2030)
5 Segment by Application
5.1 Global Conjugate Vaccines Sales by Application (2019-2030)
5.1.1 Global Conjugate Vaccines Sales by Application (2019-2024)
5.1.2 Global Conjugate Vaccines Sales by Application (2025-2030)
5.1.3 Global Conjugate Vaccines Sales Market Share by Application (2019-2030)
5.2 Global Conjugate Vaccines Revenue by Application (2019-2030)
5.2.1 Global Conjugate Vaccines Revenue by Application (2019-2024)
5.2.2 Global Conjugate Vaccines Revenue by Application (2025-2030)
5.2.3 Global Conjugate Vaccines Revenue Market Share by Application (2019-2030)
5.3 Global Conjugate Vaccines Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Conjugate Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Conjugate Vaccines Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Neuron Biotech
6.2.1 Neuron Biotech Corporation Information
6.2.2 Neuron Biotech Description and Business Overview
6.2.3 Neuron Biotech Conjugate Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Neuron Biotech Conjugate Vaccines Product Portfolio
6.2.5 Neuron Biotech Recent Developments/Updates
6.3 Serum Institute of India
6.3.1 Serum Institute of India Corporation Information
6.3.2 Serum Institute of India Description and Business Overview
6.3.3 Serum Institute of India Conjugate Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Serum Institute of India Conjugate Vaccines Product Portfolio
6.3.5 Serum Institute of India Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Conjugate Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Conjugate Vaccines Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Sanofi Pasteur
6.5.1 Sanofi Pasteur Corporation Information
6.5.2 Sanofi Pasteur Description and Business Overview
6.5.3 Sanofi Pasteur Conjugate Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sanofi Pasteur Conjugate Vaccines Product Portfolio
6.5.5 Sanofi Pasteur Recent Developments/Updates
6.6 Bharat Biotech
6.6.1 Bharat Biotech Corporation Information
6.6.2 Bharat Biotech Description and Business Overview
6.6.3 Bharat Biotech Conjugate Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bharat Biotech Conjugate Vaccines Product Portfolio
6.6.5 Bharat Biotech Recent Developments/Updates
6.7 Biological
6.6.1 Biological Corporation Information
6.6.2 Biological Description and Business Overview
6.6.3 Biological Conjugate Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biological Conjugate Vaccines Product Portfolio
6.7.5 Biological Recent Developments/Updates
6.8 GlaxoSmithKline
6.8.1 GlaxoSmithKline Corporation Information
6.8.2 GlaxoSmithKline Description and Business Overview
6.8.3 GlaxoSmithKline Conjugate Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.8.4 GlaxoSmithKline Conjugate Vaccines Product Portfolio
6.8.5 GlaxoSmithKline Recent Developments/Updates
6.9 Merck
6.9.1 Merck Corporation Information
6.9.2 Merck Description and Business Overview
6.9.3 Merck Conjugate Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Merck Conjugate Vaccines Product Portfolio
6.9.5 Merck Recent Developments/Updates
6.10 CSL
6.10.1 CSL Corporation Information
6.10.2 CSL Description and Business Overview
6.10.3 CSL Conjugate Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.10.4 CSL Conjugate Vaccines Product Portfolio
6.10.5 CSL Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Conjugate Vaccines Industry Chain Analysis
7.2 Conjugate Vaccines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Conjugate Vaccines Production Mode & Process
7.4 Conjugate Vaccines Sales and Marketing
7.4.1 Conjugate Vaccines Sales Channels
7.4.2 Conjugate Vaccines Distributors
7.5 Conjugate Vaccines Customers
8 Conjugate Vaccines Market Dynamics
8.1 Conjugate Vaccines Industry Trends
8.2 Conjugate Vaccines Market Drivers
8.3 Conjugate Vaccines Market Challenges
8.4 Conjugate Vaccines Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’